Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients.

Fiche publication

Date publication

août 2025

Journal

Annales de dermatologie et de venereologie

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Dr NARDIN Charlée

Tous les auteurs :
David C, Coquelle C, Le Corre Y, L'Orphelin JM, Nardin C, Aubin F, Cassecuel J, Dreno B, Wierzbiecka-Hainault E, Bens G, Beneton N, Dinulescu M, Kervarrec T, Saiag P, Blom A, Samimi M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40753839

Résumé

Advanced Merkel cell carcinoma (MCC) has been shown to be effectively targeted by PD-1/PD-L1 inhibitors in phase II trials and real-world studies. More than 50% of MCC patients display resistance to PD-1/PD-L1 inhibitors while identification of predictive factors for response has been inconclusive so far in this population. Our primary objective was to assess overall survival (OS) in a real-world cohort of advanced MCC patients treated with PD(L)1 inhibitors in France. Secondary objectives were to assess real-world overall response rates (rwORR), duration of response (rwDOR), progression-free survival (rwPFS) and predictive factors of response.